Sector News

Novo Nordisk target Ablynx reshuffles its board

January 11, 2018
Life sciences

Biopharmaceutical group Ablynx has made some changes to its board of directors after recently declining a takeover proposal for the second time from Novo Nordisk.

Heading up the board is Ablynx’s non-executive director Dr Bo Jesper Hensen (pictured), who was unanimously elected as its new chairman.

He succeeds Dr Peter Fellner – who has served as chairman since 2013 but resigned with immediate effect shortly after the company turned down Novo’s unsolicited offer.

Dr Hensen’s expertise lies in orphan drug research and development, international marketing and commercialisation and has experience in regulatory, pharmacovigilance, medical marketing and business development knowledge.

Dr Edwin Moses, chief executive officer at Ablynx, said: “We are very fortunate to have an extremely suitable successor with Bo Jesper, allowing for an orderly transition at this important time.

“Hensen is the ideal person to lead the board moving forward and his wealth of experience is particularly relevant as we advance towards the potential approvals and global launches of our lead, wholly-owned product, caplacizumab, in addition to advancing our extensive pipeline.”

Source: PM Live

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach